HEPARIN SODIUM - heparin sodium injection, solution
Fresenius Kabi USA, LLC

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use HEPARIN SODIUM in 0.45% SODIUM CHLORIDE INJECTION or HEPARIN SODIUM in 5% DEXTROSE INJECTION safely and effectively. See full prescribing information for HEPARIN SODIUM in 0.45% SODIUM CHLORIDE INJECTION or HEPARIN SODIUM in 5% DEXTROSE INJECTION.

HEPARIN SODIUM, for intravenous use

Initial U.S. Approval: 1939
Rx only

INDICATIONS AND USAGE
Heparin sodium is an anticoagulant indicated for:
• Prophylaxis and treatment of venous thromboembolism and pulmonary embolism
• Atrial fibrillation with embolization
• Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation)
• Prevention of clotting in arterial and cardiac surgery
• Prophylaxis and treatment of peripheral arterial embolism
• Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

DOSAGE AND ADMINISTRATION
Recommended Adult Dosages:
• Therapeutic Anticoagulant Effect with Full-Dose Heparin* (2.3)

<table>
<thead>
<tr>
<th>Intermittent Intravenous Injection</th>
<th>Initial Dose</th>
<th>10,000 units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Every 4 to 6 hours</td>
<td>5,000 to 10,000 units</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Continuous Intravenous Infusion</th>
<th>Initial Dose</th>
<th>5,000 units by intravenous injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous</td>
<td>20,000 to 40,000 units/24 hours</td>
<td></td>
</tr>
</tbody>
</table>

*Based on 150 lb. (68 kg) patient.

• Surgery of the Heart and Blood Vessels (2.5)

<table>
<thead>
<tr>
<th>Intravascular via Total Body Perfusion</th>
<th>Initial Dose</th>
<th>≥ 150 units/kg; adjust for longer procedures</th>
</tr>
</thead>
</table>

• Extracorporeal Dialysis (2.8)

Intravascular via Extracorporeal Dialysis

Follow equipment manufacturer’s operating directions carefully.

• See full prescribing information for recommended pediatric dosage. (2.4)

DOSAGE FORMS AND STRENGTHS
Heparin sodium is available as: (3)

**Heparin Sodium in 0.45% Sodium Chloride Injection:**
• Injection: 50 USP units per mL in 0.45% Sodium Chloride clear solution (25,000 USP units per 500 mL) in single-dose freeflex® bag
• Injection: 100 USP units per mL in 0.45% Sodium Chloride clear solution (25,000 USP units per 250 mL) in single-dose freeflex® bag

**Heparin Sodium in 5% Dextrose Injection:**
• Injection: 50 USP units per mL in 5% Dextrose clear solution (25,000 USP units per 500 mL) in single-dose freeflex® bag
Injection: 100 USP units per mL in 5% Dextrose clear solution (25,000 USP units per 250 mL) in single-dose freeflex® bag

--- CONTRAINDICATIONS ---

- History of Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT) (4)
- Known hypersensitivity to heparin or pork products (4)
- In whom suitable blood coagulation tests cannot be performed at appropriate intervals (4)

--- WARNINGS AND PRECAUTIONS ---

- Fatal Medication Errors: Confirm choice of correct strength prior to administration. (5.1)
- Hemorrhage: Fatal cases have occurred. Use caution in conditions with increased risk of hemorrhage. (5.2)
- HIT and HITT: Monitor for signs and symptoms and discontinue if indicative of HIT and HITT. (5.3)
- Monitoring: Blood coagulation tests guide therapy for full-dose heparin. Monitor platelet count and hematocrit in all patients receiving heparin. (5.5)

--- ADVERSE REACTIONS ---

Most common adverse reactions are hemorrhage, thrombocytopenia, HIT and HITT, hypersensitivity reactions, and elevations of aminotransferase levels. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

--- DRUG INTERACTIONS ---

Drugs that interfere with coagulation, platelet aggregation or drugs that counteract coagulation may induce bleeding. (7)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2019
Heparin sodium is indicated for:

- Prophylaxis and treatment of venous thromboembolism and pulmonary embolism;
- Atrial fibrillation with embolization;
- Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation);
- Prevention of clotting in arterial and cardiac surgery;
- Prophylaxis and treatment of peripheral arterial embolism;
- Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

2 DOSAGE AND ADMINISTRATION

2.1 Preparation for Administration

Confirm the selection of the correct formulation and strength prior to administration of the drug.

**INSTRUCTIONS FOR USE for the freeflex® Bag**

Leave bag in the overwrap until time of use.

The intact port cap provides visual tamper evidence. Do not use if port cap is prematurely removed. Maintain strict aseptic technique during handling.

**To Open:**

1. Always inspect the bag before and after removal from the overwrap.
2. Place the bag on a clean, flat surface. Starting in the bottom corner, peel the overwrap open and remove the bag.
3. Check the bag for leaks by squeezing firmly. If leaks are found, discard the bag.
4. Do not use if the solution is cloudy or a precipitate is present.
To Prepare for Administration:
1. Immediately before connecting the infusion set, firmly grasp the BLUE infusion port cap with the arrow pointing away from the bag between index finger and thumb. Gently break off the port cap. The membrane of the infusion port is sterile, and disinfection before initial use is not necessary if proper aseptic handling technique is followed.
2. Use a non-vented infusion set or close the air-inlet on a vented set. The BLUE infusion port is compatible with spike systems produced according to ISO 8536-4, with an external spike diameter of 5.5 to 5.7 mm.
3. Close the roller clamp of the infusion set.
4. Hold the base of the BLUE infusion port and insert the spike by rotating your wrist slightly until the spike is fully inserted.
5. The port membrane contains a self-sealing septum that helps prevent leakage after removing the spike. The infusion port is not intended to be spiked more than once.
6. Hang from the hole at the top of the bag.
7. For Single Use Only. Discard unused portion.

Do not admix with other drugs.
Do not use flexible container in series connections.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

2.2 Laboratory Monitoring for Efficacy and Safety
Adjust the dosage of heparin sodium according to the patient’s coagulation test results. When heparin is given by continuous intravenous infusion, determine the coagulation time approximately every 4 hours in the early stages of treatment. When the drug is administered intermittently by intravenous injection, perform coagulation tests before each injection during the early stages of treatment and at appropriate intervals thereafter. Dosage is considered adequate when the activated partial thromboplastin time (APTT) is 1.5 to 2 times the normal or when the whole blood clotting time is elevated approximately 2.5 to 3 times the control value.

Periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy.

2.3 Therapeutic Anticoagulant Effect with Full-Dose Heparin
The dosing recommendations in Table 1 are based on clinical experience. Although dosage must be adjusted for the individual patient according to the results of suitable laboratory tests, the following dosage schedules may be used as guidelines:

<table>
<thead>
<tr>
<th>Method of Administration</th>
<th>Frequency</th>
<th>Recommended Dose*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermittent Intravenous Injection</td>
<td>Initial Dose</td>
<td>10,000 units</td>
</tr>
<tr>
<td></td>
<td>Every 4 to 6 hours</td>
<td>5,000 to 10,000 units</td>
</tr>
<tr>
<td>Continuous</td>
<td>Initial Dose</td>
<td>5,000 units by intravenous injection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20,000 to 40,000 units per 24 hours</td>
</tr>
</tbody>
</table>
2.4 Pediatric Use

There are no adequate and well-controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience. In general, the following dosage schedule may be used as a guideline in pediatric patients:

Initial Dose: 75 to 100 units/kg (intravenous bolus over 10 minutes)
Maintenance Dose
- Infants: 25 to 30 units/kg/hour;
- Infants < 2 months have the highest requirements (average 28 units/kg/hour)
- Children > 1 year of age: 18 to 20 units/kg/hour;
- Older children may require less heparin, similar to weight-adjusted adult dosage
Monitoring: Adjust heparin to maintain aPTT of 60 to 85 seconds, assuming this reflects an anti-Factor Xa level of 0.35 to 0.70.

2.5 Cardiovascular Surgery

Patients undergoing total body perfusion for open-heart surgery should receive an initial dose of not less than 150 units of heparin sodium per kilogram of body weight. Frequently, a dose of 300 units per kilogram is used for procedures estimated to last less than 60 minutes or 400 units per kilogram for those estimated to last longer than 60 minutes.

2.6 Converting to Warfarin

To ensure continuous anticoagulation when converting from Heparin Sodium to warfarin, continue full heparin therapy for several days until the INR (prothrombin time) has reached a stable therapeutic range. Heparin therapy may then be discontinued without tapering [see Drug Interactions (7.1)].

2.7 Converting to Oral Anticoagulants other than Warfarin

For patients currently receiving intravenous heparin, stop intravenous infusion of heparin sodium immediately after administering the first dose of oral anticoagulant; or for intermittent intravenous administration of heparin sodium, start oral anticoagulant 0 to 2 hours before the time that the next dose of heparin was to have been administered.

2.8 Extracorporeal Dialysis

Follow equipment manufacturer’s operating directions carefully. A dose of 25 to 30 units/kg followed by an infusion rate of 1,500 to 2,000 units/hour is suggested based on pharmacodynamic data if specific manufacturers' recommendations are not available.

3 DOSAGE FORMS AND STRENGTHS

Heparin Sodium in 0.45% Sodium Chloride Injection is available as:
- Injection: 50 USP units per mL in 0.45% Sodium Chloride clear solution (25,000 USP units per 500 mL) in single-dose freeflex® bag
- Injection: 100 USP units per mL in 0.45% Sodium Chloride clear solution (25,000 USP units per 250 mL) in single-dose freeflex® bag

Heparin Sodium in 5% Dextrose Injection is available as:
Injection: 50 USP units per mL in 5% Dextrose clear solution (25,000 USP units per 500 mL) in single-dose freeflex® bag
Injection: 100 USP units per mL in 5% Dextrose clear solution (25,000 USP units per 250 mL) in single-dose freeflex® bag

4 CONTRAINDICATIONS

The use of Heparin Sodium in 0.45% Sodium Chloride Injection or Heparin Sodium in 5% Dextrose Injection is contraindicated in patients with the following conditions:

- History of Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT) [see Warnings and Precautions (5.3)]
- Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see Adverse Reactions (6.1)]
- In whom suitable blood coagulation tests — e.g., the whole blood clotting time, partial thromboplastin time, etc., — cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin) [see Warnings and Precautions (5.5)]
- An uncontrolled bleeding state [see Warnings and Precautions (5.2)], except when this is due to disseminated intravascular coagulation.

5 WARNINGS AND PRECAUTIONS

5.1 Fatal Medication Errors

Do not use this product as a “catheter lock flush” product. Heparin is supplied in various strengths. Fatal hemorrhages have occurred due to medication errors. Carefully examine all heparin products to confirm the correct container choice prior to administration of the drug.

5.2 Hemorrhage

Avoid using heparin in the presence of major bleeding, except when the benefits of heparin therapy outweigh the potential risks.

Hemorrhage, including fatal events, has occurred in patients receiving Heparin Sodium. Hemorrhage can occur at virtually any site in patients receiving heparin. Adrenal hemorrhage (with resultant acute adrenal insufficiency), ovarian hemorrhage, and retroperitoneal hemorrhage have occurred during anticoagulant therapy with heparin [see Adverse Reactions (6.1)]. A higher incidence of bleeding has been reported in patients, particularly women, over 60 years of age [see Clinical Pharmacology (12.3)]. An unexplained fall in hematocrit or fall in blood pressure should lead to serious consideration of a hemorrhagic event.

Use heparin sodium with caution in disease states in which there is increased risk of hemorrhage, including:

- **Cardiovascular** — Subacute bacterial endocarditis, severe hypertension.
- **Surgical** — During and immediately following (a) spinal tap or spinal anesthesia or (b) major surgery, especially involving the brain, spinal cord or eye.
- **Hematologic** — Conditions associated with increased bleeding tendencies, such as hemophilia, thrombocytopenia and some vascular purpuras.
- **Patients with hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy** — The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency. To reduce the risk of bleeding, reduce the heparin dose during concomitant treatment with antithrombin III (human).
- **Gastrointestinal** — Ulcerative lesions and continuous tube drainage of the stomach or small intestine.
- **Other** — Menstruation, liver disease with impaired hemostasis.

### 5.3 Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT)

HIT is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets. HIT occurs in patients treated with heparin and is due to the development of antibodies to a platelet Factor 4-heparin complex that induce *in vivo* platelet aggregation. HIT may progress to the development of venous and arterial thromboses, a condition known as heparin-induced thrombocytopenia and thrombosis (HITT). Thrombotic events may also be the initial presentation for HITT. These serious thromboembolic events include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, thrombus formation on a prosthetic cardiac valve, mesenteric thrombosis, renal arterial thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death. Monitor thrombocytopenia of any degree closely. If the platelet count falls below 100,000/mm\(^3\) or if recurrent thrombosis develops, promptly discontinue heparin, evaluate for HIT and HITT, and, if necessary, administer an alternative anticoagulant. HIT or HITT can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT or HITT.

### 5.4 Thrombocytopenia

Thrombocytopenia has been reported to occur in patients receiving heparin with a reported incidence of up to 30%. It can occur 2 to 20 days (average 5 to 9) following the onset of heparin therapy. Obtain platelet counts before and periodically during heparin therapy. Monitor thrombocytopenia of any degree closely. If the count falls below 100,000/mm\(^3\) or if recurrent thrombosis develops, promptly discontinue heparin, evaluate for HIT and, if necessary, administer an alternative anticoagulant [see Warnings and Precautions (5.3)].

### 5.5 Coagulation Testing and Monitoring

When using a full dose heparin regimen, adjust the heparin dose based on frequent blood coagulation tests. If the coagulation test is unduly prolonged or if hemorrhage occurs, heparin sodium should be discontinued promptly [see Overdosage (10)]. Periodic platelet counts, hematocrits are recommended during the entire course of heparin therapy [see Dosage and Administration (2.2)].

### 5.6 Heparin Resistance

Increased resistance to heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer, in postsurgical patients, and patients with antithrombin III deficiency. Close monitoring of coagulation tests is recommended in these cases. Adjustment of heparin doses based on anti-Factor Xa levels may be warranted.

### 5.7 Hypersensitivity

Patients with documented hypersensitivity to heparin should be given the drug only in clearly life-threatening situations [see Adverse Reactions (6.1)]. Because heparin sodium is derived from animal tissue, monitor for signs and symptoms of hypersensitivity when it is used in patients with a history of allergy.

**Heparin Sodium in 5% Dextrose Injection**

This product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Hemorrhage [see Warnings and Precautions (5.2)]
- Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT) [see Warnings and Precautions (5.3)]
- Thrombocytopenia [see Warnings and Precautions (5.4)]
- Heparin Resistance [see Warnings and Precautions (5.6)]
- Hypersensitivity [see Warnings and Precautions (5.7)]

6.1 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of heparin sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

- **Hemorrhage** – Hemorrhage is the chief complication that may result from heparin therapy [see Warnings and Precautions (5.2)]. Gastrointestinal or urinary tract bleeding during anticoagulant therapy may indicate the presence of an underlying occult lesion. Bleeding can occur at any site but certain specific hemorrhagic complications may be difficult to detect:
  - Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred with heparin therapy, including fatal cases.
  - Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive age receiving short- or long-term anticoagulant therapy.
  - Retroperitoneal hemorrhage.
- **HIT and HITT**, including delayed onset cases [see Warnings and Precautions (5.3 and 5.4)].
- **Hypersensitivity** – Generalized hypersensitivity reactions have been reported with chills, fever, and urticaria as the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions, including shock, occurring more rarely. Itching and burning, especially on the plantar side of the feet, may occur [see Warnings and Precautions (5.7)].
- **Elevations of serum aminotransferases** – Significant elevations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels have occurred in patients who have received heparin.
- **Others** – Osteoporosis following long-term administration of high-doses of heparin, cutaneous necrosis after systemic administration, suppression of aldosterone synthesis, delayed transient alopecia, priapism, and rebound hyperlipemia on discontinuation of heparin sodium have also been reported.

7 DRUG INTERACTIONS

7.1 Oral Anticoagulants

Heparin sodium may prolong the one-stage prothrombin time. Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.

7.2 Platelet Inhibitors

Drugs such as NSAIDS (including salicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used
with caution in patients receiving heparin sodium. To reduce the risk of bleeding, a reduction in the
dose of antiplatelet agent or heparin is recommended.

7.3 Other Interactions
Digitalis, tetracyclines, nicotine, antihistamines, or intravenous nitroglycerin may partially counteract
the anticoagulant action of heparin sodium.

Heparin Sodium in 5% Dextrose Injection

Intravenous nitroglycerin administered to heparinized patients may result in a decrease of the partial
thromboplastin time with subsequent rebound effect upon discontinuation of nitroglycerin. Careful
monitoring of partial thromboplastin time and adjustment of heparin dosage are recommended during
coadministration of heparin and intravenous nitroglycerin.

Antithrombin III (human) – The anticoagulant effect of heparin is enhanced by concurrent treatment with
antithrombin III (human) in patients with hereditary antithrombin III deficiency. To reduce the risk of
bleeding, a reduced dosage of heparin is recommended during treatment with antithrombin III (human).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary
There are no available data on heparin sodium use in pregnant women to inform a drug-associated risk
of major birth defects and miscarriage. In published reports, heparin exposure during pregnancy did not
show evidence of an increased risk of adverse maternal or fetal outcomes in humans. No teratogenicity,
but early embryo-fetal death was observed in animal reproduction studies with administration of heparin
sodium to pregnant rats and rabbits during organogenesis at doses approximately 10 times the maximum
recommended human dose (MRHD) of 40,000 units/24 hours infusion (see Data). Consider the benefits
and risks of Heparin Sodium in 0.45% Sodium Chloride Injection or Heparin Sodium in 5% Dextrose
Injection to a pregnant woman and possible risks to the fetus when prescribing Heparin Sodium in 0.45%
Sodium Chloride Injection or Heparin Sodium in 5% Dextrose Injection to a pregnant woman.
The estimated background risk of major birth defects and miscarriage for the indicated population is
unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In
the U.S. general population, the estimated background risk of major birth defects and miscarriage in
clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data
Human Data

The maternal and fetal outcomes associated with uses of heparin via various dosing methods and
administration routes during pregnancy have been investigated in numerous studies. These studies
generally reported normal deliveries with no maternal or fetal bleeding and no other complications.

Animal Data

In a published study conducted in rats and rabbits, pregnant animals received heparin intravenously
during organogenesis at a dose of 10,000 USP units/kg/day, approximately 10 times the maximum human
daily dose based on body weight. The number of early resorptions increased in both species. There
was no evidence of teratogenic effects.

8.2 Lactation

Risk Summary

There is no information regarding the presence of Heparin Sodium in 0.45% Sodium Chloride Injection
or Heparin Sodium in 5% Dextrose Injection in human milk, the effects on the breastfed infant, or the
effects on milk production. Due to its large molecular weight, heparin is not likely to be excreted in
human milk, and any heparin in milk would not be orally absorbed by a nursing infant. The
developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Heparin Sodium in 0.45% Sodium Chloride Injection or Heparin Sodium in 5% Dextrose Injection and any potential adverse effects on the breastfed infant from Heparin Sodium in 0.45% Sodium Chloride Injection or Heparin Sodium in 5% Dextrose Injection or from the underlying maternal condition [see Use in Specific Populations (8.4)].

8.4 Pediatric Use
There are no adequate and well-controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience [see Dosage and Administration (2.4)].

8.5 Geriatric Use
There are limited adequate and well-controlled studies in patients 65 years and older. However, a higher incidence of bleeding has been reported in patients over 60 years of age, especially women [see Warnings and Precautions (5.2)]. Lower doses of heparin may be indicated in these patients [see Clinical Pharmacology (12.3)].

10 OVERDOSAGE
Bleeding may result from heparin overdosage.

Neutralization of heparin effect
When circumstances (e.g., bleeding) require reversal of heparinization, protamine sulfate (1% solution) by slow infusion will neutralize heparin sodium.

**No more than 50 mg** should be administered, very slowly, in any 10 minute period. Each mg of protamine sulfate neutralizes approximately 100 USP units. The amount of protamine required decreases over time as heparin is metabolized. Although the metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be assumed to have a half-life of about 1/2 hour after intravenous injection.

Because fatal reactions often resembling anaphylaxis have been reported, the drug should be given only when resuscitation techniques and treatment of anaphylactoid shock are readily available.

For additional information, consult the prescribing information for Protamine Sulfate Injection, USP.

11 DESCRIPTION
Heparin is a heterogeneous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans, possessing anticoagulant properties. It is composed of polymers of alternating derivations of α-D-glucosamido (N-sulfated O-sulfated O-sulfated or N-acetylated) and O-sulfated uronic acid (α-L-iduronic acid or β-D-glucoronic acid).

Structure of Heparin Sodium (representative subunits):
Heparin Sodium in 0.45% Sodium Chloride Injection and Heparin Sodium in 5% Dextrose Injection are sterile, nonpyrogenic solutions prepared from heparin sodium (derived from porcine intestinal mucosa) for intravenous administration. The potency is determined by a biological assay using a USP reference standard based on units of heparin activity per milligram.

Heparin Sodium in 0.45% Sodium Chloride Injection, is available as follows:
Each 100 mL contains heparin sodium 5,000 or 10,000 USP Units; sodium chloride, 0.45 g; edetate disodium, dihydrate, 0.0111 g added as a stabilizer and water for injection, q.s. Each liter contains the following electrolytes: Sodium 77 mEq and chloride 77 mEq; pH 5.0 to 7.5. The solution may contain sodium hydroxide and/or hydrochloric acid for pH adjustment.

Heparin Sodium in 5% Dextrose Injection, is available as follows:
Each 100 mL contains heparin sodium 5,000 or 10,000 USP Units; dextrose hydrous, 5 g; citric acid anhydrous, 51 mg and sodium citrate dihydrate, 334 mg added as buffers; and sodium metabisulfite, 20 mg added as an antioxidant. Each liter contains the following electrolytes: Sodium 39 mEq and citrate 42 mEq; pH 5.0 to 7.5.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action
Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.

12.2 Pharmacodynamics
Bleeding time is usually unaffected by heparin. Various times (activated clotting time, activated partial thromboplastin time, prothrombin time, whole blood clotting time) are prolonged by full therapeutic doses of heparin; in most cases it is not measurably affected by low doses of heparin.

12.3 Pharmacokinetics
Absorption
Heparin is not absorbed through the gastrointestinal tract and therefore administered via parenteral route. Peak plasma concentration and the onset of action are achieved immediately after intravenous administration.
Distribution
Heparin is highly bound to antithrombin, fibrinogens, globulins, serum proteases and lipoproteins. The volume of distribution is 0.07 L/kg.
Elimination
Metabolism
Heparin does not undergo enzymatic degradation.
Excretion
Heparin is mainly cleared from the circulation by liver and reticuloendothelial cells mediated uptake into extravascular space. Heparin undergoes biphasic clearance, a) rapid saturable clearance (zero order process due to binding to proteins, endothelial cells and macrophage) and b) slower first order elimination. The plasma half-life is dose-dependent and it ranges from 0.5 to 2 h.
Specific Population
Geriatric patients
Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer activated partial thromboplastin times (APTTs) compared with patients under 60 years of age [see Use in Specific Populations (8.5)].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term studies in animals have been performed to evaluate the carcinogenic potential of heparin. Also, no studies in animals have been performed concerning mutagenesis or impairment of fertility.

16 HOW SUPPLIED/STORAGE AND HANDLING

Heparin Sodium in 0.45% Sodium Chloride Injection is supplied as follows:

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Unit of Sale</th>
<th>Strength</th>
<th>Each</th>
</tr>
</thead>
<tbody>
<tr>
<td>518077</td>
<td>NDC 63323-518-77</td>
<td>25,000 USP units per 500 mL (50 USP units per mL)</td>
<td>NDC 63323-518-01 500 mL Single Dose freeflex® Bag</td>
</tr>
<tr>
<td>517074</td>
<td>NDC 63323-517-74</td>
<td>25,000 USP units per 250 mL (100 USP units per mL)</td>
<td>NDC 63323-517-01 250 mL Single Dose freeflex® Bag</td>
</tr>
</tbody>
</table>

Heparin Sodium in 5% Dextrose Injection is supplied as follows:

<table>
<thead>
<tr>
<th>Product Code</th>
<th>Unit of Sale</th>
<th>Strength</th>
<th>Each</th>
</tr>
</thead>
<tbody>
<tr>
<td>507277</td>
<td>NDC 63323-522-77</td>
<td>25,000 USP units per 500 mL (50 USP units per mL)</td>
<td>NDC 63323-522-01 500 mL Single Dose freeflex® Bag</td>
</tr>
<tr>
<td>507374</td>
<td>NDC 63323-523-74</td>
<td>25,000 USP units per 250 mL (100 USP units per mL)</td>
<td>NDC 63323-523-01 250 mL Single Dose freeflex® Bag</td>
</tr>
</tbody>
</table>

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Do not freeze.

The container closure is not made with natural rubber latex.

Non-PVC, Non-DEHP, Sterile.

17 PATIENT COUNSELING INFORMATION

Hemorrhage

Inform patients that it may take them longer than usual to stop bleeding, that they may bruise and/or bleed more easily when they are treated with heparin, and that they should report any unusual bleeding or bruising to their physician. Hemorrhage can occur at virtually any site in patients receiving heparin. Fatal hemorrhages have occurred [see Warnings and Precautions (5.2)].
Prior to Surgery

Advise patients to inform physicians and dentists that they are receiving heparin before any surgery is scheduled [see Warnings and Precautions (5.2)].

Heparin-Induced Thrombocytopenia

Inform patients of the risk of heparin-induced thrombocytopenia (HIT). HIT may progress to the development of venous and arterial thromboses, a condition known as heparin-induced thrombocytopenia and thrombosis. HIT and HIT-T can occur up to several weeks after the discontinuation of heparin therapy [see Warnings and Precautions (5.3 and 5.4)].

Hypersensitivity

Inform patients that generalized hypersensitivity reactions have been reported [see Warnings and Precautions (5.7), Adverse Reactions (6)].

Other Medications

Because of the risk of hemorrhage, advise patients to inform their physicians and dentists of all medications they are taking, including non-prescription medications, and before starting any new medication [see Drug Interactions (7.2)].
Heparin
Heparin Sodium in
0.45% Sodium Chloride
Injection

For intravenous use only.
Single Dose Container.
Discard unused portion.
Rx only

25,000 USP units per 500 mL
(50 USP units per mL)

DO NOT ADMIX WITH OTHER DRUGS.

Each 100 mL contains:
Heparin Sodium, USP 5,000 USP units
(porcine intestinal mucosa)
Sodium Chloride, USP 0.45 g
Edetate Disodium, Dihydrate, USP 0.0111 g
Water for Injection, USP, q.s.
pH limit is 5.0 to 7.5

Electrolytes (mEq/liter):
Sodium 77 mEq
Chloride 77 mEq

Usual dosage: See package insert.

STORE AT: 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing. Use immediately once removed from overwrap.

The container closure is not made with natural rubber latex.
Non-PVC, Non-DEHP, Sterile. 403148B
FUH 0853
Mfd. for:
01-62-08-005A

FRESENIUS KABI
Lake Zurich, IL 60047
Made in Norway
www.fresenius-kabi.com/us

free flex®
Heparin
Heparin Sodium in 0.45% Sodium Chloride Injection
NDC 63323-518-77
Rx only

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing.

Manufactured for:
FRESENIUS KABI
Fresenius Kabi USA, LLC
Lake Zurich, IL 60047
www.fresenius-kabi.com/us
Made in Norway

DO NOT ADMIX WITH OTHER DRUGS.
Heparin Sodium in 0.45% Sodium Chloride Injection

25,000 USP units per 250 mL (100 USP units per mL)

For intravenous use only. Rx only
Single Dose Container. Discard unused portion.

DO NOT ADMIX WITH OTHER DRUGS.

Each 100 mL contains:
- Heparin Sodium, USP 10,000 USP units
  (porcine intestinal mucosa)
- Sodium Chloride, USP 0.45 g
- Edetate Disodium, Dihydrate, USP 0.0111 g
- Water for Injection, USP, q.s.
- pH limit is 5.0 to 7.5

Electrolytes (mEq/liter):
- Sodium 77 mEq
- Chloride 77 mEq

Sodium hydroxide, NF; Hydrochloric acid, NF for pH adjustment.

Usual dosage: See package insert.

STORE AT: 20 ° to 25°C (68° to 77°F)
[see USP Controlled Room Temperature].
Avoid excessive heat. Protect from freezing. Use immediately once removed from overwrap.
The container closure is not made with natural rubber latex.
Non-PVC, Non-DEHP, Sterile.

freeflex®
403147B
FUH 0862
01-62-08-006A

Mfd. for:
FRESERRIUS
KABI
Lake Zurich, IL 60047
Made in Norway
www.fresenius-kabi.com/us
Heparin Sodium in 0.45% Sodium Chloride Injection
NDC 63323-517-74
Rx only

Heparin Sodium in 5% Dextrose Injection
25,000 USP units per 500 mL (50 USP units per mL)
For intravenous use only.
Single Dose Container.
Discard unused portion.
Rx only
CONTAINS SULFITES. DO NOT ADMIX WITH OTHER DRUGS.
Heparin
Heparin Sodium in
5% Dextrose Injection

For intravenous use only.
Single Dose Container.
Discard unused portion.
Rx only

25,000 USP units per 500 mL
(50 USP units per mL)

CONTAINS SULFITES. DO NOT ADMIX WITH OTHER DRUGS.

Each 100 mL contains:
Heparin Sodium, USP 5,000 USP units
(porcine intestinal mucosa)
Dextrose Hydrous, USP 5 g
Sodium Citrate Dihydrate, USP 334 mg
Citric Acid Anhydrous, USP 51 mg
Sodium Metabisulfite, NF 20 mg
pH limit is 5.0 to 7.5

Electrolytes (mEq/liter):
Sodium 39 mEq
Citrate 42 mEq

Usual dosage: See package insert.

STORE AT: 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing. Use immediately once removed from overwrap.

The container closure is not made with natural rubber latex.
Non-PVC, Non-DEHP, Sterile. 403144B
FUH 0833
Mfd. for: 01-62-08-003A

FRESENIUS KABI
Lake Zurich, IL 60047
Made in Norway
www.fresenius-kabi.com/us

freeflex®
Product No. 507277
Heparin
Heparin Sodium in 5% Dextrose Injection
NDC 63323-522-77
Rx only

500 mL x 24

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid excessive heat. Protect from freezing.

Manufactured for:
FRESNIEUS KABI
Fresenius Kabi USA, LLC
Lake Zurich, IL 60047
www.fresenius-kabi.com/us
Made in Norway

Continent Sulfites. Do not admix with other drugs.

---

NDC 63323-523-01
Heparin
Heparin Sodium in 5% Dextrose Injection
25,000 USP units per 250 mL (100 USP units per mL)
For intravenous use only.
Rx only
Single Dose Container.
Discard unused portion.

CONTAINS SULFITES. DO NOT ADMIX WITH OTHER DRUGS.
Heparin Sodium in 5% Dextrose Injection

For intravenous use only. Rx only

Single Dose Container. Discard unused portion.

CONTAINS SULFITES.
DO NOT ADMIX WITH OTHER DRUGS.

Each 100 mL contains:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heparin Sodium, USP</td>
<td>10,000 USP units</td>
</tr>
<tr>
<td>(porcine intestinal mucosa)</td>
<td></td>
</tr>
<tr>
<td>Dextrose Hydrous, USP</td>
<td>5 g</td>
</tr>
<tr>
<td>Sodium Citrate Dihydrate, USP</td>
<td>334 mg</td>
</tr>
<tr>
<td>Citric Acid Anhydrous, USP</td>
<td>51 mg</td>
</tr>
<tr>
<td>Sodium Metabisulfite, NF</td>
<td>20 mg</td>
</tr>
<tr>
<td>pH limit is 5.0 to 7.5</td>
<td></td>
</tr>
</tbody>
</table>

Electrolytes (mEq/liter):

<table>
<thead>
<tr>
<th>Electrolyte</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium</td>
<td>39 mEq</td>
</tr>
<tr>
<td>Citrate</td>
<td>42 mEq</td>
</tr>
</tbody>
</table>

Usual dosage: See package insert.

STORE AT: 20° to 25°C (68° to 77°F)
[see USP Controlled Room Temperature].
Avoid excessive heat. Protect from freezing. Use immediately once removed from overwrap.

The container closure is not made with natural rubber latex.
Non-PVC, Non-DEHP, Sterile.

Mfd. for:
FRESENIUS KABI
Lake Zurich, IL 60047
Made in Norway
www.fresenius-kabi.com/us

NDC 63323-523-01
25,000 USP units per 250 mL
(100 USP units per mL)

freeflex®
403143B
FUH 0842
01-62-08-004A
### Heparin Sodium

**HEPARIN SODIUM**

heparin sodium injection, solution

#### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC: 63323-522</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INTRAVENOUS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEPARIN SODIUM (UNII: ZZ45AB24CA) (HEPARIN - UNII:T2410KM04A)</td>
<td>HEPARIN</td>
<td>5000 [USP‘U] in 100 mL</td>
</tr>
</tbody>
</table>

#### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEXTROSE MONOHYDRATE (UNII: LX22YL083G)</td>
<td></td>
</tr>
<tr>
<td>ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)</td>
<td></td>
</tr>
<tr>
<td>TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)</td>
<td></td>
</tr>
<tr>
<td>SODIUM METABISULFITE (UNII: 4VON5FNS3C)</td>
<td></td>
</tr>
<tr>
<td>Packaging</td>
<td>#</td>
</tr>
<tr>
<td>-----------</td>
<td>---</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Marketing Information</th>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NDA</td>
<td>NDA017029</td>
<td>08/24/2017</td>
<td></td>
</tr>
</tbody>
</table>

HEPARIN SODIUM
heparin sodium injection, solution

<table>
<thead>
<tr>
<th>Product Information</th>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDA:63323-523</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Route of Administration</td>
<td>INTRAVENOUS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active Ingredient/Active Moiety</th>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEPARIN SODIUM (UNII: ZZ45AB24CA) (HEPARIN - UNII:T2410KM04A)</td>
<td>HEPARIN</td>
<td></td>
<td>10000 [USP'U] in 100 mL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inactive Ingredients</th>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEXTROSE MONOHYDRATE (UNII: LX22YL083G)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM METABISULFITE (UNII: 4V0N5FNS3C)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Packaging</th>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>NDC:63323-523-74</td>
<td>24 in 1 CASE</td>
<td>08/24/2017</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>NDC:63323-523-01</td>
<td>250 mL in 1 BAG; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Marketing Information</th>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NDA</td>
<td>NDA017029</td>
<td>08/24/2017</td>
<td></td>
</tr>
</tbody>
</table>
## Heparin Sodium

**heparin sodium injection, solution**

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>Route of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td>NDC:63323-517</td>
<td>INTRAVENOUS</td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEPARIN SODIUM (UNII: ZZ45AB24CA) (HEPARIN - UNII:T2410KM04A)</td>
<td>HEPARIN</td>
<td>10000 [USPU] in 100 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CHLORIDE (UNII: 451W47IQ8X)</td>
<td></td>
</tr>
<tr>
<td>EDETATE DISODIUM (UNII: 7FLD91C86K)</td>
<td></td>
</tr>
<tr>
<td>SODIUM HYDROXIDE (UNII: 55X04QC32I)</td>
<td></td>
</tr>
<tr>
<td>HYDROCHLORIC ACID (UNII: QTT17582CB)</td>
<td></td>
</tr>
<tr>
<td>WATER (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:63323-517-74</td>
<td>24 in 1 CASE</td>
<td>08/24/2017</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:63323-517-01</td>
<td>250 mL in 1 BAG; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA017029</td>
<td>08/24/2017</td>
<td></td>
</tr>
</tbody>
</table>
### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM CHLORIDE</td>
<td>(UNII: 451W47IQ8X)</td>
</tr>
<tr>
<td>EDETATE DISODIUM</td>
<td>(UNII: 7FLD91C86K)</td>
</tr>
<tr>
<td>WATER</td>
<td>(UNII: 059QF0KO0R)</td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:63323-518-77</td>
<td>24 in 1 CASE</td>
<td>08/24/2017</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:63323-518-01</td>
<td>500 mL in 1 BAG; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA017029</td>
<td>08/24/2017</td>
<td></td>
</tr>
</tbody>
</table>

### Labeler - Fresenius Kabi USA, LLC (608775388)

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresenius Kabi Norge AS</td>
<td>731170932</td>
<td>analysis(63323-517, 63323-518, 63323-522, 63323-523), manufacture(63323-517, 63323-518, 63323-522, 63323-523)</td>
<td></td>
</tr>
</tbody>
</table>

Revised: 2/2020